Indicators of the quality of care for inflammatory bowel diseases in the tertiary center

The aim of the study. There was a study of indicators of the quality of care provided in a comparative aspect at the primary level, as well as at the specialized level of the tertiary center.

Materials and methods. Retrospective analysis of outpatients and inpatients with IBD followed at a tertiary center. Analyzed quality indicators: time to start therapy at the onset of the disease; proper use of steroids; monitoring the safety of immunobiological therapy and others.

Results and discussion. The prevailing majority of patients were observed in general gastroenterologists (75.2% with Crohn's disease and 53.6% with ulcerative colitis, respectively, p<0.021, than in gastroenterologists specializing in IBD (24.8% and 46.4%, respectively, p><0.021). Patients with Crohn's disease were significantly more often diagnosed after the first emergency hospitalization (59.4%, p<0,012) first-time inpatient therapy was prescribed (58.8%, p<0,002), surgical intervention was more often required (36.2% p<0,002), as well as more than 2 courses of steroids (27.9%, p<0,030). Before the appointment of immunosuppressive therapy, tuberculosis screening is carried out in 68.6% of cases of IBD, testing for viral hepatitis - 83.5% of cases; Cl. Difficile and CMV, if indicated, were excluded only in a third of patients with IBD (28.2%, p<0,046 and 38,3%, p<0,024 respectively). IBD specialists are more likely to be referred for primary endoscopic examination (82.3%) in comparison with PHC specialists (52.4%, p<0,01). Regular (endoscopic) screening for dysplasia, taking into account risk factors, was performed only in 41.2% in CD and 30.8% in UC; the recommendation was given in 62.9% of cases by IBD specialists and 20.6% of cases by primary care physicians

Conclusions. Given the complex nature of the pathology, the lifelong disabling course, it is necessary to expand access to specialized care, raise awareness of primary care specialists about early diagnosis measures, pathogenetic therapy aimed at preventing complications.

1. Влияние COVID-19 на воспалительные заболевания кишечника: течение и исходы / А. С. Танабаева, И. В. Губонина, В. Б. Гриневич и др. //Наука и Здравоохранение. – 2022. – №4 (24). – С. 12-18. doi: 10.34689/SH.2022.24.4.002.

2. Приказ и. о. МЗ РК от 29 марта 2023 года № 48. Зарегистрирован в МЮ РК 31 марта 2023 года № 32185 //https://adilet.zan.kz/rus/docs/V2300032185 (дата обращения: 12.01.2024 г.).

3. Приказ Министра здравоохранения Республики Казахстан от 5 августа 2021 года № ҚР ДСМ - 75. Зарегистрирован в Министерстве юстиции Республики Казахстан 6 августа 2021 года №23885 //https://adilet.zan.kz/rus/docs/V2100023885 (дата обращения: 12.01.2024 г.).

4. 28 quality of care initiative improves outcomes for patients with inflammatory bowel disease / G. Melmed, B. Oliver, J. Houet al. //Gastroenterology. – 2020. – V. 158. – S88.

5. Chen Y. Core indicators of an evaluation and guidance system for quality of care in inflammatory bowel disease centers: A critical review /Y. Chen, J. Shen //eClinicalMedicine. – 2022. – V. 46. – 101382.

6. Codesign and implementation of an equitypromoting national health literacy programme for people living with inflammatory bowel disease (IBD): a protocol for the application of the Optimising Health Literacy and Access (Ophelia) process /M. Hawkins, W. Massuger, C. Cheng et al. //BMJ. – 2021. – V. 11. – e045059. doi:10.1136/bmjopen-2020-04505.

7. Daperno M. Endoscopy in IBD: When and How? //Diagnostics. – 2023. – V. 13 (22). – 3423.

8. Harmonization of quality of care in an IBD center impacts disease outcomes: Importance of structure, process indicators and rapid access clinic / Ye. J. Reinglas, S. Restellini, L. Gonczi et al //Digestive and Liver Disease. – 2019. – V. 51. – P. 340-345.

9. Inflammatory Bowel Disease data collection reference guide. Version 1.0.1 /A. Kim, S. Vermeire, P. Kotze et al. – Oxford: Academic Health Science Network, 2017. – 315 p.

10. Quality of Care’ Standards in Inflammatory Bowel Disease: A Systematic Review /G. Fiorino, M. Allocca, M. Chaparro et al. //Journal of Crohn's and Colitis. – 2019. – V. 13. – P. 127-137.

11. Quraishi M. N. Establishing key performance indicators for inflammatory bowel disease in the UK /M. N. Quraishi, E. Dobson, R. Ainley //Frontline Gastroenterology. – 2023. – V. 14. – P. 407-414.

12. Sustained Improvement in Inflammatory Bowel Disease Quality Measures Using an Electronic Health Record Intervention /A. Bensinger, F. Wilson, P. Green et al. //Appl. Clin. Inform. – 2019. – V. 10 (5). – P. 918-926.

13. The 2023 impact of Inflammatory Bowel Disease in Canada: access to and models of care / H. Mathias, N. Rohatinsky, S. K. Murthy et al. //Journal of the Canadian Association of Gastroenterology. – 2023. – V. 6. – P. 111-121.

14. Trends in IBD incidence and prevalence across epidemiologic stages: a global systemic review with meta-analysis /J. Gorospe, J. Windsor, L. Hracs et al. //Gastroenterology. – 2024. – V. 166. – P. 56-57.